Vivos Therapeutics Enters Agreement to Exercise 1,982,356 Warrants
Vivos Therapeutics has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023, and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered for resale pursuant to effective registration statement on Form S-3. The gross proceeds to the company from the exercise of the warrants are expected to be approximately $4.64 million, prior to deducting placement agent fees and offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. As consideration for the exercise of such existing warrants for cash, the Company will issue in a private placement new unregistered warrants to purchase up to an aggregate of 3,964,712 shares of common stock at an exercise price of $2.09 per share, which warrants will be exercisable immediately upon issuance and, with respect to warrants to purchase up to 1,982,356 shares of common stock, will expire five years following the date of issuance, and with respect to warrants to purchase up to 1,982,356 shares of common stock, will expire twenty-four months following the date of issuance. The offering is expected to close on or about January 20, subject to satisfaction of customary closing conditions
Discover Tomorrow's Bullish Stocks Today
Analyst Views on VVOS
About VVOS
About the author

Vivos Therapeutics Closes Exercise of 1.98M Warrants, Raising $4.64M
- Successful Financing: Vivos Therapeutics has successfully exercised 1,982,356 warrants, raising approximately $4.64 million, demonstrating the company's active presence in capital markets and enhancing its operational funding.
- New Warrants Issued: In exchange for cash exercise, the company issued 3,964,712 new warrants at an exercise price of $2.09 per share, which is expected to further improve the company's capital structure and financing flexibility.
- Market Positioning: Vivos focuses on treating obstructive sleep apnea (OSA) with its innovative devices cleared by the FDA, indicating significant market potential that is likely to attract more investor interest.
- Future Development Plans: The company intends to use the proceeds for working capital and general corporate purposes, reflecting its confidence in future growth and ability to seize market opportunities.

Vivos Therapeutics (VVOS) Exercises Warrants for $4.64M in Funding
- Financing Agreement: Vivos Therapeutics has entered into an agreement for the immediate exercise of warrants, expected to raise approximately $4.64 million, indicating the company's active engagement in capital markets and funding capabilities.
- Warrant Details: The warrants exercised involve 1.98 million shares, with exercise prices reduced from $3.83 to $2.34, reflecting the company's adaptability to market conditions and commitment to shareholder value.
- New Warrants Issuance: As part of the transaction, Vivos will issue new warrants for 3.96 million shares at an exercise price of $2.09, enhancing investor participation and providing flexibility for future financing.
- Clear Use of Funds: The net proceeds from this offering will be used for working capital and general corporate purposes, demonstrating the company's strategic intent to expand operations and improve efficiency.









